Search

Your search keyword '"Vilcu, Ana-Maria"' showing total 46 results
Start Over Author "Vilcu, Ana-Maria"
46 results on '"Vilcu, Ana-Maria"'

3. Prevalence and bleeding risk associated with the concomitant use of direct oral anticoagulants and antiarrhythmic drugs in patients with atrial fibrillation, based on the French healthcare insurance database

Author

Gosselin, Laëtitia, Vilcu, Ana-Maria, Souty, Cécile, Steichen, Olivier, Launay, Titouan, Conte, Cécile, Saint-Salvi, Béatrice, Turbelin, Clément, Sarazin, Marianne, Blanchon, Thierry, Hanslik, Thomas, Lapeyre-Mestre, Maryse, and Rossignol, Louise

Published
2023
Full Text
View/download PDF

7. Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016–17 and 2017–18)

Author

Kissling, Esther, Pozo, Francisco, Buda, Silke, Vilcu, Ana-Maria, Rizzo, Caterina, Gherasim, Alin, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Meijer, Adam, Paradowska-Stankiewicz, Iwona, Machado, Ausenda, Vučina, Vesna Višekruna, Lazar, Mihaela, Johansen, Kari, Dürrwald, Ralf, van der Werf, Sylvie, Bella, Antonino, Larrauri, Amparo, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Dijkstra, Frederika, Bogusz, Joanna, Guiomar, Raquel, Filipović, Sanja Kurečić, Pitigoi, Daniela, Penttinen, Pasi, and Valenciano, Marta

Published
2019
Full Text
View/download PDF

8. Influenza‐like illness in individuals treated with immunosuppressants, biologics, and/or systemic corticosteroids for autoimmune or chronic inflammatory disease: A crowdsourced cohort study, France, 2017–2018

Author

Greffe, Ségolène, primary, Guerrisi, Caroline, additional, Souty, Cécile, additional, Vilcu, Ana‐Maria, additional, Hayem, Gilles, additional, Costantino, Félicie, additional, Padovano, Ilaria, additional, Bourgault, Isabelle, additional, Trad, Salim, additional, Ponsoye, Matthieu, additional, Vilaine, Eve, additional, Debin, Marion, additional, Turbelin, Clément, additional, Blanchon, Thierry, additional, and Hanslik, Thomas, additional

Published
2023
Full Text
View/download PDF

11. Risk of hospitalisation for serious colchicine intoxication after concomitant exposure to pristinamycin: A nationwide healthcare database study

Author

Souty, Cécile, primary, Vilcu, Ana-Maria, additional, Conte, Cécile, additional, Saint-Salvi, Béatrice, additional, Sarazin, Marianne, additional, Rossignol, Louise, additional, Blanchon, Thierry, additional, Hanslik, Thomas, additional, Lapeyre-Mestre, Maryse, additional, and Steichen, Olivier, additional

Published
2022
Full Text
View/download PDF

12. Influenza vaccine effectiveness against influenza A subtypes in Europe: results from the 2021–22 I-MOVE primary care multicentre study

Author

Kissling, Esther, primary, Pozo, Francisco, additional, Martínez-Baz, Iván, additional, Buda, Silke, additional, Vilcu, Ana-Maria, additional, Domegan, Lisa, additional, Ateca, Clara Mazagatos, additional, Dijkstra, Frederika, additional, Latorre-Margalef, Neus, additional, Filipovićović, Sanja Kurečić, additional, Machado, Ausenda, additional, Lazar, Mihaela, additional, Buesa, Itziar Casado, additional, Dürrwald, Ralf, additional, Werf, Sylvie van der, additional, O'Donnell, Joan, additional, Dopido, Juan Antonio Linares, additional, Meijer, Adam, additional, Riess, Maximilian, additional, Vučina, Vesna Višekruna, additional, Rodrigues, Ana Paula, additional, Mihai, Maria Elena, additional, Castilla, Jesus, additional, Goerlitz, Luise, additional, Falchi, Alessandra, additional, Connell, Jeff, additional, Castrillejo, Daniel, additional, Hooiveld, Mariette, additional, Carnahan, AnnaSara, additional, Ilić, Maja, additional, Guiomar, Raquel, additional, Ivanciuc, Alina-Elena, additional, Maurel, Marine, additional, Omokanye, Ajibol, additional, and Valenciano, Marta, additional

Published
2022
Full Text
View/download PDF

13. Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned

Author

Bagaria, Jayshree, Jansen, Tessa, Marques, Diogo Fp, Hooiveld, Mariette, McMenamin, Jim, de Lusignan, Simon, Vilcu, Ana-Maria, Meijer, Adam, Rodrigues, Ana-Paula, Brytting, Mia, Mazagatos, Clara, Cogdale, Jade, van der Werf, Sylvie, Dijkstra, Frederika, Guiomar, Raquel, Enkirch, Theresa, Valenciano, Marta, I-MOVE-COVID-19 study team, Larrauri, Amparo, Pozo Sanchez, Francisco, Casas Flecha, Inmaculada, Unión Europea. Comisión Europea. H2020, Public Health Scotland [Glasgow], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), EpiConcept [Paris], University of Oxford, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Public Health Agency of Sweden, Institute of Health Carlos III, UK Health Security Agency (UKHSA), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673., MOVE-COVID-19 study team: Esther Kissling, Lisa Domegan, Joan O'Donnell, Josephine Murray, Virginia Sandonis Martín, Iván Martínez-Baz, Ausenda Machado, Itziar Casado, Sylvie Behillil, Amparo Larrauri, Ruby Tsang, Marit de Lange, Maximilian Riess, Jesús Castilla, Mark Hamilton, Alessandra Falchi, Francisco Pozo, Linda Dunford, Cristina Burgui, Debbie Sigerson, Thierry Blanchon, Eva María Martínez Ochoa, Jeff Connell, Joanna Ellis, Rianne van Gageldonk-Lafeber, Irina Kislaya, Angela Mc Rose, Jamie Lopez Bernal, Nick Andrews, Inmaculada Casas Flecha, Janine Thoulass, Baltazar Nunes, Verónica Gomez, Rita Sa Machado, Vincent Enouf, Pedro Licinio Pinto Leite, Anna Molesworth, Adele McKenna, Janine Thoulass, European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), HAL-SU, Gestionnaire, Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic - I-MOVE-COVID-19 - - H2020-SC1-PHE-CORONAVIRUS-20202020-03-16 - 2022-06-15 - 101003673 - VALID, UK Health Security Agency [London] (UKHSA), and Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur)

Subjects
Epidemiology, Sentinel surveillance, primary care, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Virology, Influenza, Human, Humans, Influenza-Like Illness, Pandemics, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Primary Health Care, SARS-CoV-2, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Influenza-Like Illness (ILI), COVID-19, Estados de Saúde e de Doença, Primary care, Europe, Vigilância Epidemiológica, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Influenza Vaccines, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Sentinel Surveillance
Abstract

I-MOVE-COVID-19 study team: Esther Kissling, Lisa Domegan, Joan O’Donnell, Josephine Murray, Virginia Sandonis Martín, Iván Martínez-Baz, Ausenda Machado, Itziar Casado, Sylvie Behillil, Amparo Larrauri, Ruby Tsang, Marit de Lange, Maximilian Riess, Jesús Castilla, Mark Hamilton, Alessandra Falchi, Francisco Pozo, Linda Dunford, Cristina Burgui, Debbie Sigerson, Thierry Blanchon, Eva María Martínez Ochoa, Jeff Connell, Joanna Ellis, Rianne van Gageldonk-Lafeber, Irina Kislaya, Angela MC Rose, Jamie Lopez Bernal, Nick Andrews, Inmaculada Casas Flecha, Janine Thoulass, Baltazar Nunes, Verónica Gomez, Rita Sa Machado, Vincent Enouf, Pedro Licinio Pinto Leite, Anna Molesworth, Adele McKenna, Janine Thoulass As the COVID-19 pandemic began in early 2020, primary care influenza sentinel surveillance networks within the Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE) consortium rapidly adapted to COVID-19 surveillance. This study maps system adaptations and lessons learned about aligning influenza and COVID-19 surveillance following ECDC / WHO/Europe recommendations and preparing for other diseases possibly emerging in the future. Using a qualitative approach, we describe the adaptations of seven sentinel sites in five European Union countries and the United Kingdom during the first pandemic phase (March–September 2020). Adaptations to sentinel systems were substantial (2/7 sites), moderate (2/7) or minor (3/7 sites). Most adaptations encompassed patient referral and sample collection pathways, laboratory testing and data collection. Strengths included established networks of primary care providers, highly qualified testing laboratories and stakeholder commitments. One challenge was the decreasing number of samples due to altered patient pathways. Lessons learned included flexibility establishing new routines and new laboratory testing. To enable simultaneous sentinel surveillance of influenza and COVID-19, experiences of the sentinel sites and testing infrastructure should be considered. The contradicting aims of rapid case finding and contact tracing, which are needed for control during a pandemic and regular surveillance, should be carefully balanced. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. info:eu-repo/semantics/publishedVersion

Published
2022
Full Text
View/download PDF

14. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

Author

Kissling, Esther, Hooiveld, Mariëtte, Martínez-Baz, Iván, Mazagatos, Clara, William, Naoma, Vilcu, Ana-Maria, Kooijman, Marjolein N, Ilić, Maja, Domegan, Lisa, Machado, Ausenda, de Lusignan, Simon, Lazar, Mihaela, Meijer, Adam, Brytting, Mia, Casado, Itziar, Larrauri, Amparo, Murray, Josephine-L K, Behillil, Sylvie, de Gier, Brechje, Mlinarić, Ivan, O'Donnell, Joan, Rodrigues, Ana Paula, Tsang, Ruby, Timnea, Olivia, de Lange, Marit, Riess, Maximilian, Castilla, Jesús, Pozo Sanchez, Francisco, Hamilton, Mark, Falchi, Alessandra, Knol, Mirjam J, Kurečić Filipović, Sanja, Dunford, Linda, Guiomar, Raquel, Cogdale, Jade, Cherciu, Carmen, Jansen, Tessa, Enkirch, Theresa, Basile, Luca, Connell, Jeff, Gomez, Verónica, Sandonis-Martin, Virginia, Bacci, Sabrina, Rose, Angela Mc, Pastore Celentano, Lucia, Valenciano, Marta, I-MOVE-COVID-19, ECDC primary care study teams, Conde-San Román, Patricia, Casas Flecha, Inmaculada, Oliva Dominguez, Jesus Angel, Delgado-Sanz, Concepcion, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Croatian Institute of Public Health [Zagreb] (CIPH), Health Service Executive [Dublin] (HSE), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), University of Oxford, Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Public Health Agency of Sweden, Instituto de Salud Carlos III [Madrid] (ISC), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Biologie des ARN et virus influenza - RNA Biology of Influenza Virus (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), University College Dublin [Dublin] (UCD), UK Health Security Agency [London] (UKHSA), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), I-MOVE-COVID-19 and ECDC primary care study team Katica Čusek Adamić, Ivana Ferenčak, Bernard Kaić, Mirjana Lana Kosanović Ličina, Danijela Lakošeljac, Ivana Mihin Huskić, Diana Nonković, Nick Andrews, Jamie Lopez Bernal, Joanna Ellis, Heather Whitaker, Thierry Blanchon, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Lois O'Connor, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Rianne van Gageldonk-Lafeber, Susan J Hahné, Hester E de Melker, Ewout B Fanoy, Stijn Raven, Marit Middeldorp, Irina Kislaya, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Amélia Soeiro, Maria Elena Mihai, Iulia Bistriceanu, Alina Ivanciuc, Diana Dintoi, Catalina Pascu, Adrian Jidovu, Debbie Sigerson, Diogo Fp Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Inmaculada Casas Flecha, Ana Martínez Mateo, Daniel Castrillejo, Eva María Martínez Ochoa, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Cristina Burgui, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Pasi Penttinen, Christiana Carstairs, University of St Andrews. School of Medicine, Unión Europea. Comisión Europea. H2020, and European Centre for Disease Prevention and Control

Subjects
Test-negative design, RM, Delta variant, COVID-19 Vaccines, Epidemiology, [SDV]Life Sciences [q-bio], Multicentre study, Influenza, Human/prevention & control, MESH: Primary Health Care, Europe/epidemiology, MESH: Influenza Vaccines, SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Virology, Influenza, Human, Humans, MESH: COVID-19, MESH: SARS-CoV-2, COVID-19/epidemiology, Vaccine effectiveness, QR355, MESH: Humans, Primary Health Care, vaccine effectiveness, SARS-CoV-2, MESH: Influenza, Human, Vaccination, test-negative design, Public Health, Environmental and Occupational Health, COVID-19, 3rd-DAS, MESH: Vaccination, NIS, multicentre study, RM Therapeutics. Pharmacology, Europe, Influenza Vaccines, MESH: COVID-19 Vaccines, SARS-COV-2, vaccine efffectiveness, MESH: Europe, QR355 Virology
Abstract

Introduction In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results Overall VE was 74% (95% CI: 69–79), 76% (95% CI: 71–80), 63% (95% CI: 48–75) and 63% (95% CI: 16–83) among those aged 30–44, 45–59, 60–74 and ≥ 75 years, respectively. VE among those aged 30–59 years was 78% (95% CI: 75–81), 66% (95% CI: 58–73), 91% (95% CI: 87–94) and 52% (95% CI: 40–61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52–77), 65% (95% CI: 48–76) and 83% (95% CI: 64–92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30–59 years was 87% (95% CI: 83–89) at 14–29 days and 65% (95% CI: 56–71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.

Published
2022
Full Text
View/download PDF

15. Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France

Author

Decarreaux, Dorine, primary, Pouquet, Marie, additional, Souty, Cecile, additional, Vilcu, Ana-Maria, additional, Prévot-Monsacre, Pol, additional, Fourié, Toscane, additional, Villarroel, Paola Mariela Saba, additional, Priet, Stephane, additional, Blanché, Hélène, additional, Sebaoun, Jean-Marc, additional, Deleuze, Jean-François, additional, Turbelin, Clément, additional, Werner, Andréas, additional, Kochert, Fabienne, additional, Grosgogeat, Brigitte, additional, Rabiega, Pascaline, additional, Laupie, Julien, additional, Abraham, Nathalie, additional, Guerrisi, Caroline, additional, Noël, Harold, additional, Van der Werf, Sylvie, additional, Carrat, Fabrice, additional, Hanslik, Thomas, additional, Charrel, Remi, additional, De Lamballerie, Xavier, additional, Blanchon, Thierry, additional, and Falchi, Alessandra, additional

Published
2022
Full Text
View/download PDF

16. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study

Author

Kissling, Esther, Pozo, Francisco, Martínez‐Baz, Iván, Buda, Silke, Vilcu, Ana‐Maria, Domegan, Lisa, Mazagatos, Clara, Dijkstra, Frederika, Latorre‐Margalef, Neus, Kurečić Filipović, Sanja, Machado, Ausenda, Lazar, Mihaela, Casado, Itziar, Dürrwald, Ralf, van der Werf, Sylvie, O'Donnell, Joan, Linares Dopido, Juan Antonio, Meijer, Adam, Riess, Maximilian, Višekruna Vučina, Vesna, Rodrigues, Ana Paula, Mihai, Maria Elena, Castilla, Jesús, Goerlitz, Luise, Falchi, Alessandra, Connell, Jeff, Castrillejo, Daniel, Hooiveld, Mariette, Carnahan, Annasara, Ilić, Maja, Guiomar, Raquel, Ivanciuc, Alina, Maurel, Marine, Omokanye, Ajibola, Valenciano, Marta, I‐MOVE study team, European Centre for Disease Prevention and Control, EpiConcept [Paris], Institute of Health Carlos III, CIBER de Epidemiología y Salud Pública (CIBERESP), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], Robert Koch Institute [Berlin] (RKI), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Health Service Executive [Dublin] (HSE), National Institute for Public Health and the Environment [Bilthoven] (RIVM), University of Kalmar, Croatian Institute of Public Health [Zagreb] (CIPH), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Dirección General de Salud Pública, Public Health Agency of Sweden, Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Cantacuzino National Medico-Military Institute for Research Development [Bucharest], Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, University College Dublin [Dublin] (UCD), School of Social Sciences. Campus de Melilla. Univeristy of Granada, Netherlands Institute for Health Services Research [Utrecht] (NIVEL), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), and tudy teams are very grateful to all patients, general practitioners, paediatricians, laboratory teams, and regional epidemiologists who have contributed to the studies. Participating laboratories submitted their sequences to GISAID (www.gisaid.org) for easy sharing with the central laboratory in Madrid. We would like to acknowledge Mia Brytting, who sadly passed away before publication. She is deeply missed.

Subjects
Pulmonary and Respiratory Medicine, Male, Adult, Adolescent, Epidemiology, [SDV]Life Sciences [q-bio], Vaccine Efficacy, Multicentre study, Young Adult, Influenza A Virus, H1N1 Subtype, Influenza, Human, Humans, Europe, influenza, influenza vaccine, multicentre study, vaccine effectiveness, Child, Aged, Vaccine effectiveness, Primary Health Care, Influenza vaccine, Influenza A Virus, H3N2 Subtype, Vaccination, Public Health, Environmental and Occupational Health, Infant, Newborn, Infant, Middle Aged, vaccine effectiveness, multicentre study, Influenza, Europe, Infectious Diseases, Influenza Vaccines, Case-Control Studies, Child, Preschool, Female, influenza vaccine, influenza
Abstract

Background: In 2021-2022, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure influenza vaccine effectiveness (VE). Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT-PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions. Results: Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43-89) and 81% (95% CI: 45-93) among those aged 15-64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12-42) and 25% (95% CI: -41 to 61), 33% (95% CI: 14-49), and 26% (95% CI: -22 to 55) among those aged 0-14, 15-64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: -6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2. Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021-2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza. This project has received funding from the European Centre for Disease Prevention and Control with in the framework contract ECDC/2018/029. Sí

Published
2022
Full Text
View/download PDF

17. Is the Alpha Variant of SARS-CoV-2 Associated with a Higher Viral Load Than the Historical Strain in Saliva Samples in Patients with Mild to Moderate Symptoms?

Author

Bonnet, Camille, primary, Masse, Shirley, additional, Benamar, Hayat, additional, Vilcu, Ana-Maria, additional, Swital, Morgane, additional, Hanslik, Thomas, additional, van der Werf, Sylvie, additional, Duval, Xavier, additional, Carrat, Fabrice, additional, Falchi, Alessandra, additional, and Blanchon, Thierry, additional

Published
2022
Full Text
View/download PDF

18. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children

Author

Kissling, Esther, Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, van der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, I-MOVE/I-MOVE+ study team, EpiConcept [Paris], National Centre for Microbiology [Madrid], Instituto de Salud Carlos III [Madrid] (ISC), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), Department for Infectious Disease Epidemiology [Berlin], Robert Koch Institute [Berlin] (RKI), Department of Infectious Diseases [Rome, Italy], Istituto Superiore di Sanita, CIBER de Epidemiología y Salud Pública (CIBERESP), National Centre for Epidemiology. CIBERNED. Carlos III Institute of Health, Madrid, Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III [Madrid] (ISC)-Instituto de Salud Carlos III [Madrid] (ISC), National Centre for Epidemiology [Budapest], Public Health Agency of Sweden, Health Protection Surveillance Centre (HPSC), National Institute of Public Health - National Institute of Hygiene [Poland], National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Croatian Institute of Public Health [Zagreb] (CIPH), Génétique moléculaire des virus à ARN ((U-Pasteur_ 2 / UMR_3569)), Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), National Reference Centre for Influenza [Berlin], European Centre for Disease Prevention and Control (ECDC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Istituto Superiore di Sanità (ISS), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), Instituto de Salud Carlos III (ISC), CIBER de Enfermedades Neurodegenerativas (CIBERNED), National Institute of Public Health – National Institute of Hygiene [Varsovie], Instituto Nacional de Saúde Doutor Ricardo Jorge [Lisboa], European Centre for Disease Prevention and Control, Kissling, Esther, Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, van der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, and D'Agaro, Pierlanfranco

Subjects
Male, 0301 basic medicine, Epidemiology, viruses, Influenza B viru, vaccine effectivene, Efetividade da Vacina Antigripal, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, Influenza A Virus, Medicine, 030212 general & internal medicine, Child, Vaccine effectiveness, I-MOVE+, virus diseases, Middle Aged, multicentre study, 3. Good health, Europe, Infectious Diseases, Influenza Vaccines, Child, Preschool, Original Article, Female, Case-Control Studie, influenza, Human, Adult, Pulmonary and Respiratory Medicine, Trivalent influenza vaccine, Lineage (genetic), Adolescent, Influenza vaccine, case-control study, 030106 microbiology, Influenza season, Young Adult, 03 medical and health sciences, Influenza, Human, Humans, I-MOVE, H1N1 Subtype, Vacina Antigripal, ddc:610, Preschool, Aged, vaccine effectiveness, case‐control study, business.industry, Cuidados de Saúde, Public Health, Environmental and Occupational Health, Case-control study, Infant, Influenza a, Original Articles, influenza vaccine, Case-Control Studies, Influenza B virus, Case Control Study, Virology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, vaccine effe, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, 610 Medizin und Gesundheit, business
Abstract

BACKGROUND: During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. METHODS: We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. RESULTS: We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: -38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: -4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was -47.6% (95% CI: -124.9 to 3.1), 27.3% (95% CI: -4.6 to 49.4) and 9.3% (95% CI: -44.1 to 42.9), respectively. CONCLUSIONS: Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine. ECDC has contributed fund for the coordination and some study sites under the Framework contract no. ECDC/2014/026 for the individuals aged less than 65 years. The I‐MOVE/I‐MOVE+ study team is very grateful to all patients, general practitioners, paediatricians, hospital teams, laboratory teams and regional epidemiologists who have contributed to the study. We acknowledge the authors, originating and submitting laboratories of the sequences from GISAID's EpiFlu Database used for this study. All submitters of data may be contacted directly via the GISAID website http://www.gisaid.org. Sí

Published
2018
Full Text
View/download PDF

19. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre study analysis by age-group, vaccine brand and time since vaccination, I-MOVE-COVID-19 and ECDC networks, July–August 2021

Author

Kissling, Esther, primary, Hooiveld, Mariëtte, additional, Martínez-Baz, Iván, additional, Mazagatos, Clara, additional, William, Naoma, additional, Vilcu, Ana-Maria, additional, Kooijman, Marjolein N., additional, Ilić, Maja, additional, Domegan, Lisa, additional, Machado, Ausenda, additional, de Lusignan, Simon, additional, Lazar, Mihaela, additional, Meijer, Adam, additional, Brytting, Mia, additional, Casado, Itziar, additional, Larrauri, Amparo, additional, Murray, Josephine-L K., additional, Behillil, Sylvie, additional, de Gier, Brechje, additional, Mlinarić, Ivan, additional, O'Donnell, Joan, additional, Rodrigues, Ana Paula, additional, Tsang, Ruby, additional, Timnea, Olivia, additional, de Lange, Marit, additional, Riess, Maximilian, additional, Castilla, Jesús, additional, Pozo, Francisco, additional, Hamilton, Mark, additional, Falchi, Alessandra, additional, Knol, Mirjam J., additional, Filipović, Sanja Kurečić, additional, Dunford, Linda, additional, Guiomar, Raquel, additional, Cogdale, Jade, additional, Cherciu, Carmen, additional, Jansen, Tessa, additional, Enkirch, Theresa, additional, Basile, Luca, additional, Connell, Jeff, additional, Gomez, Verónica, additional, Martín, Virginia Sandonis, additional, Bacci, Sabrina, additional, Rose, Angela MC, additional, Celentano, Lucia Pastore, additional, and Valenciano, Marta, additional

Published
2021
Full Text
View/download PDF

20. Risk of bleeding associated with nonsteroidal anti‐inflammatory drug use in patients exposed to antithrombotic therapy: a case‐crossover study

Author

Paternoster, Morgane, primary, Steichen, Olivier, additional, Lapeyre‐Mestre, Maryse, additional, Blanchon, Thierry, additional, Rossignol, Louise, additional, Vilcu, Ana‐Maria, additional, Launay, Titouan, additional, Sarazin, Marianne, additional, Bagheri, Haleh, additional, Conte, Cécile, additional, Turbelin, Clément, additional, Hanslik, Thomas, additional, and Souty, Cécile, additional

Published
2021
Full Text
View/download PDF

21. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study.

Author

Kissling, Esther, Pozo, Francisco, Martínez‐Baz, Iván, Buda, Silke, Vilcu, Ana‐Maria, Domegan, Lisa, Mazagatos, Clara, Dijkstra, Frederika, Latorre‐Margalef, Neus, Kurečić Filipović, Sanja, Machado, Ausenda, Lazar, Mihaela, Casado, Itziar, Dürrwald, Ralf, van der Werf, Sylvie, O'Donnell, Joan, Linares Dopido, Juan Antonio, Meijer, Adam, Riess, Maximilian, and Višekruna Vučina, Vesna

Subjects
H1N1 influenza, FLU vaccine efficacy, PRIMARY care, RESPIRATORY infections, INFLUENZA vaccines, INFLUENZA A virus, INFLUENZA
Abstract

Background: In 2021–2022, influenza A viruses dominated in Europe. The I‐MOVE primary care network conducted a multicentre test‐negative study to measure influenza vaccine effectiveness (VE). Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT‐PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions. Results: Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43–89) and 81% (95% CI: 45–93) among those aged 15–64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12–42) and 25% (95% CI: −41 to 61), 33% (95% CI: 14–49), and 26% (95% CI: −22 to 55) among those aged 0–14, 15–64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: −6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2. Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021–2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I‐MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory‐confirmed influenza. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care : I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Author

Kissling, Esther, Hooiveld, Mariette, Sandonis Martín, Virginia, Martínez-Baz, Iván, William, Naoma, Vilcu, Ana-Maria, Mazagatos, Clara, Domegan, Lisa, de Lusignan, Simon, Meijer, Adam, Machado, Ausenda, Brytting, Mia, Casado, Itziar, Murray, Josephine-L K., Belhillil, Sylvie, Larrauri, Amparo, O’Donnell, Joan, Tsang, Ruby, de Lange, Marit, Rodrigues, Ana Paula, Riess, Maximilian, Castilla, Jesús, Hamilton, Mark, Falchi, Alessandra, Pozo, Francisco, Dunford, Linda, Cogdale, Jade, Jansen, Tessa, Guiomar, Raquel, Enkirch, Theresa, Burgui, Cristina, Sigerson, Debbie, Blanchon, Thierry, Martínez Ochoa, Eva María, Connell, Jeff, Ellis, Joanna, van Gageldonk-Lafeber, Rianne, Kislaya, Irina, Rose, Angela MC, Valenciano, Marta, Andrews, Nick, Lopez Bernal, Jamie, Whitaker, Heather, Guerrisi, Caroline, Launay, Titouan, Masse, Shirley, van der Werf, Sylvie, Enouf, Vincent, Cuddihy, John, McKenna, Adele, Joyce, Michael, de Gascun, Cillian, Moran, Joanne, Miqueleiz, Ana, Navascués, Ana, Trobajo-Sanmartín, Camino, Ezpeleta, Carmen, Moreno, Paula López, Gorricho, Javier, Ardanaz, Eva, Baigorria, Fernando, Barricarte, Aurelio, de la Cruz, Enrique, Egüés, Nerea, García Cenoz, Manuel, Guevara, Marcela, Moreno-Iribas, Conchi, Sayón, Carmen, Gomez, Verónica, Nunes, Baltazar, Roquete, Rita, Silva, Adriana, Melo, Aryse, Costa, Inês, Verdasca, Nuno, Conde, Patrícia, Marques, Diogo FP, Molesworth, Anna, Quinn, Leanne, Leyton, Miranda, Campbell, Selin, Thoulass, Janine, McMenamin, Jim, Mateo, Ana Martínez, Basile, Luca, Castrillejo, Daniel, Quiñones Rubio, Carmen, Delgado-Sanz, Concepción, Oliva., Jesús, University of St Andrews. School of Medicine, team, I-MOVE-COVID-19 primary care study, above), I-MOVE-COVID-19 primary care study team (in addition to authors, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Instituto de Salud Carlos III [Madrid] (ISC), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Health Service Executive [Dublin] (HSE), University of Oxford, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Public Health Agency of Sweden, Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, Institut National de la Santé et de la Recherche Médicale (INSERM), University College Dublin [Dublin] (UCD), Public Health England [London], Dirección General de Salud Pública, This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673., European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), and Unión Europea. Comisión Europea. H2020

Subjects
Infecções Respiratórias, Adult, Test-negative design, 2019-20 coronavirus outbreak, Pediatrics, medicine.medical_specialty, RM, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Primary health care, Primary care, 030204 cardiovascular system & hematology, Multicentre study, 03 medical and health sciences, Elderly, 0302 clinical medicine, SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Virology, Medicine, Humans, 030212 general & internal medicine, Aged, Vaccine effectiveness, QR355, vaccine effectiveness, Primary Health Care, business.industry, SARS-CoV-2, Efetividade da vacina contra COVID-19, test-negative design, Public Health, Environmental and Occupational Health, COVID-19, 3rd-DAS, NIS, Estados de Saúde e de Doença, multicentre study, 3. Good health, RM Therapeutics. Pharmacology, Vaccination, Europe, Determinantes da Saúde e da Doença, business, QR355 Virology, Rapid Communication
Abstract

I-MOVE-COVID-19 primary care study team (in addition to authors above): Nick Andrews, Jamie Lopez Bernal, Heather Whitaker, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Verónica Gomez, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Diogo FP Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Ana Martínez Mateo, Luca Basile, Daniel Castrillejo, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva. The I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight countries. We measured overall and product-specific COVID-19 VE against symptomatic SARS-CoV-2 infection among those aged 65 years and older. We also measured VE by time since vaccination. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. info:eu-repo/semantics/publishedVersion

Published
2021
Full Text
View/download PDF

25. Absence of association between 2019-20 influenza vaccination and COVID-19: Results of the European I-MOVE-COVID-19 primary care project, March-August 2020

Author

Kissling, Esther, Hooiveld, Mariëtte, Brytting, Mia, Vilcu, Ana-Maria, de Lange, Marit, Martínez-Baz, Iván, Sigerson, Debbie, Enkirch, Theresa, Belhillil, Sylvie, Meijer, Adam, Castilla, Jesus, William, Naoma, Carnahan, AnnaSara, Falchi, Alessandra, Hendriksen, Janneke, Casado, Itziar, Murray, Josie, Enouf, Vincent, Dijkstra, Frederika, Marques, Diogo F P, and Valenciano, Marta

Subjects
SARS-CoV-2, case-control study, test-negative design, COVID-19, influenza vaccination, multicentre study
Published
2021

26. Baisse de l’incidence de plusieurs maladies infectieuses en médecine générale depuis le début de la pandémie de COVID-19

Author

Bardoulat, Isabelle, primary, Launay, Titouan, additional, Souty, Cécile, additional, Vilcu, Ana-Maria, additional, Turbelin, Clément, additional, Guerrisi, Caroline, additional, Hanslik, Thomas, additional, Colizza, Vittoria, additional, Boëlle, Pierre-Yves, additional, Lemaître, Magali, additional, and Blanchon, Thierry, additional

Published
2021
Full Text
View/download PDF

27. Are Posterior Oropharyngeal Saliva Specimens an Acceptable Alternative to Nasopharyngeal Sampling for the Monitoring of SARS-CoV-2 in Primary-Care Settings?

Author

Masse, Shirley, primary, Bonnet, Camille, additional, Vilcu, Ana-Maria, additional, Benamar, Hayat, additional, Swital, Morgane, additional, van der Werf, Sylvie, additional, Carrat, Fabrice, additional, Hanslik, Thomas, additional, Blanchon, Thierry, additional, and Falchi, Alessandra, additional

Published
2021
Full Text
View/download PDF

28. Initial risk perception and feeling of preparedness of primary care physicians regarding the COVID-19 pandemic in Belgium, France and Spain in February 2020

Author

GUERRISI, Caroline, primary, Thomas, Bérenger, additional, Diez, Ana Ordax, additional, Cauteren, Dieter Van, additional, Alonso, Jose Eugenio Lozano, additional, Moreels, Sarah, additional, Falchi, Alessandra, additional, Alonso, Tomàs Vega, additional, Bonmarin, Isabelle, additional, Raude, Jocelyn, additional, Vilcu, Ana-Maria, additional, Hanslik, Thomas, additional, Debin, Marion, additional, Rossignol, Louise, additional, Colizza, Vittoria, additional, Souty, Cécile, additional, and Blanchon, Thierry, additional

Published
2021
Full Text
View/download PDF

29. Risk of Bleeding Associated With Nonsteroidal Anti‐inflammatory Drug Use in Patients Exposed to Antithrombotic Therapy: A Case‐Crossover Study.

Author

Paternoster, Morgane, Steichen, Olivier, Lapeyre‐Mestre, Maryse, Blanchon, Thierry, Rossignol, Louise, Vilcu, Ana‐Maria, Launay, Titouan, Sarazin, Marianne, Bagheri, Haleh, Conte, Cécile, Turbelin, Clément, Hanslik, Thomas, and Souty, Cécile

Subjects
HEMORRHAGE risk factors, FIBRINOLYTIC agents, CONFIDENCE intervals, NONSTEROIDAL anti-inflammatory agents, GASTROINTESTINAL hemorrhage, PHARMACOLOGY, ANTICOAGULANTS, RISK assessment, HOSPITAL care, PLATELET aggregation inhibitors, CROSSOVER trials, STATISTICAL sampling, LOGISTIC regression analysis, ODDS ratio, DISEASE risk factors
Abstract

Concomitant nonsteroidal anti‐inflammatory drug (NSAIDs) and antithrombotic drug use is associated with an increased risk of bleeding, mainly gastrointestinal. The goal of this study was to quantify the transient increase in the risk of hospitalization for bleeding associated with NSAID use in patients treated with antiplatelet agents or anticoagulants. We performed a unidirectional case‐crossover study using the EGB (Échantillon généraliste de bénéficiaires), a permanent random sample of the French nationwide health database. Patients receiving antithrombotic therapy and hospitalized for bleeding between 2009 and 2017 were included. We compared their NSAID exposure during a 15‐day hazard window immediately before hospital admission to 3 earlier 15‐day control windows. The risk of hospitalization for bleeding associated with the recent use of NSAIDs was estimated using conditional logistic regression to estimate odds ratios (ORs). During the study period, 33 patients treated with anticoagulants and 253 treated with antiplatelet agents received NSAIDs and were included in the case‐crossover analysis. We found an increased risk of hospitalization for gastrointestinal bleeding after exposure to NSAIDs, with an adjusted OR of 3.59 (95%CI, 1.58‐8.17) in patients receiving anticoagulant therapy and 1.44 (95%CI, 1.07‐1.94) in patients receiving antiplatelet therapy. The risk of nongastrointestinal bleeding was also increased after exposure to NSAIDs with an adjusted OR of 2.72 (95%CI, 1.23‐6.04) in patients exposed to anticoagulant therapy. The risk of gastrointestinal and nongastrointestinal bleeding increases after NSAID use in patients treated with anticoagulants, while the risk of gastrointestinal bleeding increases, but to a lesser extent in those treated with antiplatelets. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Absence of association between 2019‐20 influenza vaccination and COVID‐19: Results of the European I‐MOVE‐COVID‐19 primary care project, March‐August 2020

Author

Kissling, Esther, primary, Hooiveld, Mariëtte, additional, Brytting, Mia, additional, Vilcu, Ana‐Maria, additional, de Lange, Marit, additional, Martínez‐Baz, Iván, additional, Sigerson, Debbie, additional, Enkirch, Theresa, additional, Belhillil, Sylvie, additional, Meijer, Adam, additional, Castilla, Jesus, additional, William, Naoma, additional, Carnahan, AnnaSara, additional, Falchi, Alessandra, additional, Hendriksen, Janneke, additional, Casado, Itziar, additional, Murray, Josie, additional, Enouf, Vincent, additional, Dijkstra, Frederika, additional, Marques, Diogo F. P., additional, and Valenciano, Marta, additional

Published
2021
Full Text
View/download PDF

31. Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort

Author

Kissling, Esther, Pozo, Francisco, Buda, Silke, Vilcu, Ana-Maria, Gherasim, Alin, Brytting, Mia, Domegan, Lisa, Gomez, Veronica, Meijer, Adam, Lazar, Mihaela, Vucina, Vesna Visekruna, Duerrwald, Ralf, van der Werf, Sylvie, Larrauri, Amparo, Enkirch, Theresa, O'Donnell, Joan, Guiomar, Raquel, Hooiveld, Mariette, Petrovic, Goranka, Stoian, Elena, Penttinen, Pasi, Valenciano, Marta, Preuss, Ute, Tolksdorf, Kristin, Biere, Barbara, Smallfield, Maria, Wedde, Marianne, Falchi, Alessandra, Masse, Shirley, Villechenaud, Natacha, Souty, Cecile, Blanchon, Thierry, Launay, Titouan, Enouf, Vincent, Behillil, Sylvie, Lina, Bruno, Valette, Martine, Mazagatos, Clara, Casas, Inmaculada, Garcia Comas, Luis, Insua Marisquerena, Maria Esther, Carlos Galan, Juan, Castilla, Jesus, Garcia Cenoz, Manuel, Navascues, Ana, Quinones Rubio, Carmen, Ibanez Perez, Ana Carmen, Martinez Ochoa, Eva, Blasco, Miriam, Gimenez Duran, Jaume, Maria Vanrell, Juana, Reina, Jordi, Castrillejo, Daniel, Wiman, Asa, Hunt, Meadhbh, Joyce, Michael, Levis, Olga, Collins, Claire, Dunford, Linda, Bennett, Charlene, Moran, Joanne, Tuite, Grainne, Connell, Jeff, de Gascun, Cillian, Rodrigues, Ana Paula, Machado, Ausenda, Nunes, Baltazar, Kislaya, Irina, Costa, Ines, Conde, Patricia, Cristovao, Paula, Pechirra, Pedro, Borges, Vitor, Bagheri, Mariam, van den Brink, Sharon, Dijkstra, Frederika, Goderski, Gabriel, van der Hoek, Wim, de Lange, Marit, Marzec, Ton, Overduin, Pieter, Reukers, Daphne, Teirlinck, Anne, Wijsman, Lisa, Donker, Ge, Mihai, Maria Elena, Cherciu, Carmen Maria, Alexandrescu, Viorel, Kaic, Bernard, Filipovic, Sanja Kurecic, Novosel, Iva Pem, Makaric, Zvjezdana Lovric, Zajec, Martina, Drazenovic, Vladimir, Moren, Alain, I-MOVE Primary Care Study Team, EpiConcept [Paris], Instituto de Salud Carlos III [Madrid] (ISC), Robert Koch Institute [Berlin] (RKI), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Agency of Sweden, Health Protection Surveillance Centre (HPSC), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), and Netherlands Institute for Health Services Research [Utrecht] (NIVEL)

Subjects
vacunas de la gripe, Male, 0301 basic medicine, potencia vacunal, Epidemiology, [SDV]Life Sciences [q-bio], humanos, Gripe, adolescente, Hemagglutinin Glycoproteins, Influenza Virus, virus de la influenza A, 0302 clinical medicine, infecciones del tracto respiratorio, memoria inmunológica, vigilancia centinela, Determinantes de Saúde e Doença, Medicine, 030212 general & internal medicine, Respiratory Tract Infections, mediana edad, Vaccine effectiveness, anciano, birth cohorts, Birth cohorts, Estado de Saúde e Doença, resultado del tratamiento, Vaccination, Age Factors, Imprinting, adulto, Middle Aged, multicentre study, Europe, Treatment Outcome, Influenza A virus, Época 2018-2019, Influenza Vaccines, Population Surveillance, Female, Seasons, imprinting, influenza, Birth cohort, A(H3N2), Adult, Adolescent, Primary care, Multicentre study, vacunación, 03 medical and health sciences, vigilancia de la población, Virology, Influenza, Human, Humans, ddc:610, Vacina Antigripal, EuroEVA, Vaccine Potency, Aged, vaccine effectiveness, business.industry, Influenza A Virus, H3N2 Subtype, Research, Efetividade, Public Health, Environmental and Occupational Health, Influenza a, Influenza, estaciones (meteorología), 030104 developmental biology, influenza vaccination, test negative case control, vaccine effectiveness, 610 Medizin und Gesundheit, business, Immunologic Memory, Sentinel Surveillance, Demography
Abstract

Introduction Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe in 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences in vaccine effectiveness (VE). Aim The I-MOVE multicentre primary care test-negative study assessed 2018/19 influenza A(H3N2) VE by age and genetic subgroups to explore VE by birth cohort. Methods We measured VE against influenza A(H3N2) and (sub)clades. We stratified VE by usual age groups (0–14, 15–64, ≥ 65-years). To assess the imprint-regulated effect of vaccine (I-REV) hypothesis, we further stratified the middle-aged group, notably including 32–54-year-olds (1964–86) sharing potential childhood imprinting to serine at haemagglutinin position 159. Results Influenza A(H3N2) VE among all ages was −1% (95% confidence interval (CI): −24 to 18) and 46% (95% CI: 8–68), −26% (95% CI: −66 to 4) and 20% (95% CI: −20 to 46) among 0–14, 15–64 and ≥ 65-year-olds, respectively. Among 15–64-year-olds, VE against clades 3C.2a1b and 3C.3a was 15% (95% CI: −34 to 50) and −74% (95% CI: −259 to 16), respectively. VE was −18% (95% CI: −140 to 41), −53% (95% CI: −131 to −2) and −12% (95% CI: −74 to 28) among 15–31-year-olds (1987–2003), 32–54-year-olds (1964–86) and 55–64-year-olds (1954–63), respectively. Discussion The lowest 2018/19 influenza A(H3N2) VE was against clade 3C.3a and among those born 1964–86, corresponding to the I-REV hypothesis. The low influenza A(H3N2) VE in 15–64-year-olds and the public health impact of the I-REV hypothesis warrant further study.

Published
2019
Full Text
View/download PDF

32. Influenza epidemics observed in primary care from 1984 to 2017 in France: A decrease in epidemic size over time

Author

Souty, Cécile, Amoros, Philippe, Falchi, Alessandra, Capai, Lisandru, Bonmarin, Isabelle, van der Werf, Sylvie, Masse, Shirley, Turbelin, Clément, Rossignol, Louise, Vilcu, Ana‐Maria, Lévy‐Bruhl, Daniel, Lina, Bruno, Minodier, Laëtitia, Dorléans, Yves, Guerrisi, Caroline, Hanslik, Thomas, Blanchon, Thierry, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), EA Bioscope Corse Méditerranée : Dynamique des infections virales en milieu insulaire, Université Pascal Paoli (UPP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Santé publique France - French National Public Health Agency [Saint-Maurice, France], Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Virpath-Grippe, de l'émergence au contrôle -- Virpath-Influenza, from emergence to control (Virpath), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR - laboratoire associé), Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Ambroise Paré [AP-HP], We thank all general practitioners and paediatricians participating in the French Sentinelles network., Santé publique France, Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Institut Pasteur [Paris], Génétique moléculaire des virus à ARN ((U-Pasteur_ 2 / UMR_3569)), Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires, Laboratoire de Virologie, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, Hôpital Ambroise Paré, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pascal Paoli (UPP), and Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR)

Subjects
Male, Time Factors, Vaccination Coverage, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Child, MESH: Incidence, Child, Letter to the Editor, MESH: Aged, influenza‐like illness, MESH: France/epidemiology, Incidence, MESH: Influenza, Human, Vaccination, MESH: Infant, Newborn, MESH: Vaccination Coverage, Middle Aged, MESH: Infant, MESH: Young Adult, Child, Preschool, surveillance, Original Article, Female, France, influenza, Adult, Adolescent, MESH: Epidemics/statistics & numerical data, influenza-like illness, epidemics, MESH: Primary Health Care, Young Adult, primary care, Influenza, Human, Humans, Aged, MESH: Adolescent, MESH: Humans, Primary Health Care, MESH: Time Factors, MESH: Child, Preschool, Infant, Newborn, Infant, MESH: Adult, Original Articles, MESH: Vaccination, MESH: Male, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Sentinel Surveillance, MESH: Female
Abstract

International audience; BACKGROUND: Epidemiological analysis of past influenza epidemics remains essential to understand the evolution of the disease and optimize control and prevention strategies. Here, we aimed to use data collected by a primary care surveillance system over the last three decades to study trends in influenza epidemics and describe epidemic profiles according to circulating influenza viruses.METHODS: Influenza-like illness (ILI) weekly incidences were estimated using cases reported by general practitioners participating in the French Sentinelles network, between 1984 and 2017. Influenza epidemics were detected by applying a periodic regression to this time series. Epidemic (co-)dominant influenza virus (sub)types were determined using French virology data.RESULTS: During the study period, 297 607 ILI cases were reported allowing the detection of 33 influenza epidemics. On average, seasonal epidemics lasted 9 weeks and affected 4.1% of the population (95% CI 3.5; 4.7). Mean age of cases was 29 years. Epidemic size decreased over time by -66 cases per 100 000 population per season on average (95% CI -132; -0.2, P value = 0.049) and epidemic height decreased by -15 cases per 100 000 (95% CI -28; -2, P value = 0.022). Epidemic duration appeared stable over time. Epidemics were mostly dominated by A(H3N2) (n = 17, 52%), associated with larger epidemic size, higher epidemic peak and older age of cases.CONCLUSIONS: The declining trend in influenza epidemic size and height over the last 33 years might be related to several factors like increased vaccine coverage, hygiene improvements or changing in influenza viruses. However, further researches are needed to assess the impact of potential contributing factors to adapt influenza plans.

Published
2019
Full Text
View/download PDF

33. Association Between Acute Gastroenteritis and Continuous Use of Proton Pump Inhibitors During Winter Periods of Highest Circulation of Enteric Viruses

Author

Vilcu, Ana-Maria, Sabatte, Laure, Blanchon, Thierry, Souty, Cecile, Maravic, Milka, Lemaitre, Magali, Steichen, Olivier, Hanslik, Thomas, Gestionnaire, HAL Sorbonne Université 5, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), IQVIA, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire d'Informatique Médicale et Ingénierie des Connaissances en e-Santé (LIMICS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Sorbonne Paris Nord, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), and Hôpital Ambroise Paré [AP-HP]

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

International audience; Importance: An increased risk of acute bacterial enteric infections has been reported among patients receiving proton pump inhibitor (PPI) therapy. The risk of acute gastroenteritis (AGE) of viral origin associated with continuous PPI exposure has been less studied.Objective: To investigate the association between continuous PPI therapy and AGE occurrence during winter epidemic periods when the circulation of enteric viruses is the highest.Design, setting, and participants: A matched cohort study was performed using a prospectively collected drug dispensing database from a large panel of community pharmacies in continental France. All patients recorded in the database during the 2015 to 2016 winter season, with documented age, sex, and use of an identifiable regular panel pharmacy, were eligible for the study. Each patient exposed to continuous PPI therapy was matched to 3 unexposed patients, according to year of birth, sex, and identifiable regular panel pharmacy. Analyses were performed between January 2017 and December 2018.Exposure: Continuous PPI use during the 2015 to 2016 AGE winter epidemic.Main outcomes and measures: The occurrence of at least 1 AGE episode during the 2015 to 2016 AGE winter epidemic was the main outcome. Episodes of AGE were identified using a previously validated algorithm based on drug dispensing data. Relative risks of AGE were estimated using a multivariable log-binomial model adjusted for age, sex, and treatments for chronic conditions.Results: There were 233 596 patients receiving PPI therapy (median [interquartile range] age, 71 [62-81] years; 55.8% female) and 626 887 matched patients not receiving PPI therapy (median [interquartile range] age, 70 [61-80] years; 56.3% female) included in the analyses. At least 1 AGE epidemic episode was identified in 3131 patients (1.3%) receiving PPI therapy and in 4327 patients (0.7%) not receiving PPI therapy. The adjusted relative risk of AGE for those receiving PPI therapy was 1.81 (95% CI, 1.72-1.90) for all ages considered, 1.66 (95% CI, 1.54-1.80) among those aged 45 to 64 years, 2.19 (95% CI, 1.98-2.42) among those aged 65 to 74 years, and 1.98 (95% CI, 1.82-2.15) among those aged 75 years and older.Conclusions and relevance: Continuous PPI therapy was associated with an increased risk of developing AGE during periods of highest circulation of enteric viruses. These findings support the hypothesis that PPI use is associated with an increased risk of enteric viral infections.

Published
2019
Full Text
View/download PDF

34. Surveillance de la grippe en France, saison 2017-2018

Author

Bernard-Stoecklin, Sibylle, Campèse, Christine, Savitch, Yann, Fouillet, Anne, Sommen, Cécile, Bruhl, Daniel, Behillil, Sylvie, Enouf, Vincent, van Der Werf, Sylvie, Valette, Martine, Bouscambert-Duchamp, Maude, Lina, Bruno, Guerrisi, Caroline, Souty, Cécile, Turbelin, Clément, Launay, Titouan, Vilcu, Ana-Maria, Hanslik, Thomas, Blanchon, Thierry, Santé publique France - French National Public Health Agency [Saint-Maurice, France], Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Centre National de Référence des Virus des Infections Respiratoires (dont la Grippe) [Lyon] (CNR - laboratoire associé), Institut des Agents Infectieux [Lyon] (IAI), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), and Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; This article summarizes influenza activity in France for the 2017-2018 season.Methods –This report is based on different sources of data collected in France: clinical influenza-like illness (ILI) in the community reported by the primary health care networks, virological data analysed by reference laboratories, emergency units visits and hospitalizations for clinical influenza, reporting of severe influenza cases hospitalised in intensive care units (ICU), reporting of acute respiratory infections (ARI) clusters in nursing homes, and mortality data.Results –In France, the 2017-18 season started early-December in mainland France, peaked on the last week of December and ended at the end of March, lasting 16 weeks. The epidemic was characterized by an atypical dynamics with two consecutive waves due to the circulation ofA(H1N1)pdm09 followed by B/Yamagata lineage viruses. Its impact was moderate in the community, but high numbers of hospitalizations (>9,700) and severe cases admitted to ICUs (>2,900) were recorded. During the epidemic, a marked excess mortality was observed, with 13,000 deaths attributed to influenza.Conclusion –The 2017-18 influenza epidemic started early and was unusually long, with an atypical dynamics and marked severity. The successive circulation of A(H1N1)pdm09 and B/Yamagata viruses, together with insufficient vaccine coverage and suboptimal vaccine effectiveness, have contributed to this severity. It confirms the high impact of the disease for the population at risk and strengthens the need for prevention especially higher vaccine coverage among people at risk, and the implementation of control measures to limit the spread of the virus around the cases, as well as the utility of early antiviral treatment for subjects at risk.; Cet article présente le bilan épidémiologique et virologique de l’épidémie grippale en France durant la saison 2017-2018.Méthode –Ce bilan s’appuie sur l’analyse descriptive des données de surveillance de la grippe ou des syndromes grippaux transmises par les réseaux de médecine ambulatoire, les analyses virologiques des laboratoires partenaires, la surveillance des passages aux urgences et des hospitalisations codées grippe, la surveillance des cas graves de grippe hospitalisés en services de réanimation, les signalements d’épisodes d’infections respiratoires aiguës (IRA) dans les collectivités de personnes âgées et les données de mortalité.Résultats –L’épidémie de grippe a débuté début décembre en France métropolitaine, a atteint son pic au cours de la dernière semaine de décembre et s’est terminée fin mars, soit 16 semaines d’épidémie. Elle a présenté une dynamique atypique, avec deux vagues successives dues à la circulation majoritaire du virus A(H1N1)pdm09 puis à celle du virus B Lignage Yamagata. L’épidémie a été d’intensité modérée en médecine ambulatoire mais elle a été caractérisée par un nombre élevé d’hospitalisations après recours aux urgences pour syndrome grippal (>9 700) et de cas graves admis en réanimation (>2 900). Cette épidémie a également été marquée par une surmortalité importante, avec 13 000 décès attribués à la grippe.Conclusion –L’épidémie de grippe 2017-2018, précoce et exceptionnellement longue, a été caractérisée par une dynamique atypique et une importante sévérité, liées à la circulation successive des virus A(H1N1)pdm09 et B/Yamagata, dans un contexte de couverture vaccinale insuffisante et d’efficacité vaccinale sous-optimale. Son impact important sur les hospitalisations et la mortalité rappelle la gravité de la maladie et l’intérêt de la prévention, à savoir la vaccination chez les personnes à risque, complétée de mesures barrières afin de limiter la diffusion du virus dans l’entourage des cas, ainsi que l’utilité d’un traitement antiviral précoce, particulièrement chez les sujets à risque.

Published
2018

35. Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically-attended influenza: results of the European I-MOVE multicentre test-negative case-control study, 2011/12-2016/17

Author

Valenciano, Marta, Kissling, E, Larrauri, Amparo, Nunes, Baltasar, Pitigoi, Daniela, O Donnell, Joan, Reuss, Annicka, Horváth, Judit Krisztina, Paradowska-Stankiewicz, Iwona, Rizzo, Caterina, Falchi, Alessandra, Daviaud, Isabel, Brytting, Mia, Meijer, Adam, Kaic, Bernard, Gherasim, Alin, Machado, Ausenda, Ivanciuc, Alina, Domegan, Lisa, Schweiger, Brunhilde, Ferenczi, Annamária, Korczyńska, Monika, Bella, Antonino, Vilcu, Ana-Maria, Mosnier, Anne, Zakikhany, Katherina, Filipovićović, Sanja Kurečić, Johansen, Kari, Moren, Alain, and de Lange, Marit

Subjects
virus diseases
Abstract

Results of previous influenza vaccination effects on current season influenza vaccine effectiveness (VE) are inconsistent.

Published
2018

38. SURVEILLANCE DE LA GRIPPE EN FRANCE, SAISON 2016-2017

Author

Campèse, Christine, Bonmarin, Isabelle, Savitch, Yann, Fouillet, Anne, Sommen, Cécile, Lévy-Bruhl, Daniel, Guerrisi, Caroline, Souty, Cécile, Turbelin, Clément, Launay, Titouan, Vilcu, Ana-Maria, Hanslik, Thomas, Behillil, Sylvie, Enouf, Vincent, van Der Werf, Sylvie, Institut de Veille Sanitaire (INVS), Santé publique France - French National Public Health Agency [Saint-Maurice, France], Santé publique France Guyane, Haut Conseil de la Santé Publique (HCSP), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie des maladies infectieuses et modélisation (ESIM), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Plateforme de Microbiologie Mutualisée (PIBnet) - Mutualized Platform for Microbiology (P2M), Pasteur International Bioresources network (PIBNet), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), and Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité)

Subjects
France Influenza, Surveillance, [SDV]Life Sciences [q-bio], Vaccination, Grippe, Grippe Surveillance Épidémie Vaccination France Influenza Surveillance Outbreak Vaccination France, Outbreak, France, Épidémie
Abstract

International audience; This article summarizes the influenza activity in France for the 2016-17 season.Methods – This report is based on the descriptive analysis of different sources of data on influenza or influenza- like illness collected in mainland France: influenza clinical activity in the community reported by the primary health care network, virological data analysed by reference laboratories, emergency units visits and hospitali- zations for clinical influenza, reporting of acute respiratory infections (ARI) clusters in nursing homes, reporting of severe influenza cases hospitalised in intensive care units (ICU) and mortality data.Results – In mainland France, the 2016-17 season was characterized by a moderate influenza epidemic in the community which started in mid-December, peaked mid-January and lasted 10 weeks. Sub-type A(H3N2) viruses were the almost exclusive circulating influenza viruses. The impact of the influenza epidemic was espe- cially severe among the elderly (65 years old and more) with a high proportion of hospitalisations for influenza among outpatients presenting to emergency ward (16% of 40 000 outpatients) and a high proportion of patients aged above 65 years (69%) among hospitalized patients. This age group accounted for 67% of the 1,479 cases admitted to intensive care. During the epidemic wave, a marked excess mortality estimate at 14,400 deaths attributable to influenza was observed. Over 90% of this excess affected people 75 years old and more.Conclusion – The 2016-17 influenza epidemic was early, moderate, and particularly severe among the elderly. This severity is due to the almost exclusive circulation of A(H3N2) viruses in a context of low vaccine coverage and sub-optimal vaccine effectiveness. It confirms the severity of the disease for the population at risk and strengthens the need for prevention, especially a higher vaccine coverage among people at risk and the implementation of non-pharmaceutical control measures to limit the spread of the virus around cases.; Cet article présente le bilan épidémiologique et virologique de l’activité grippale en France durant la saison 2016-2017.Méthodes – Ce bilan s’appuie sur l’analyse descriptive des données de surveillance de la grippe ou des syndromes grippaux transmises par les réseaux de médecine ambulatoire, les analyses virologiques des laboratoires partenaires, les signalements d’épisodes d’infections respiratoires aiguës (IRA) dans les collec- tivités de personnes âgées, la surveillance des passages aux urgences et des hospitalisations codées grippe, la surveillance des cas graves de grippe hospitalisés en services de réanimation et les données de mortalité.Résultats – L’épidémie de grippe a débuté mi-décembre et a atteint son pic mi-janvier pour se terminer début février, soit une durée totale de 10 semaines. Due quasi-exclusivement au virus grippal de type A(H3N2), elle a été d’intensité modérée en milieu ambulatoire mais a eu un impact important chez les personnes âgées. Elle a été caractérisée par une part importante d’hospitalisations parmi les passages aux urgences pour syndrome grippal (16% des 40 000 passages) et par une proportion importante des 65 ans et plus parmi les patients hospitalisés (69%). Cette tranche d’âge a représenté 67% des 1 479 cas de grippe admis en réanimation. Cette épidémie a également été marquée par un excès de mortalité estimé à 14 400 décès attribuables à la grippe, dont plus de 90% chez les personnes de 75 ans et plus.Conclusion – L’épidémie de grippe 2016-2017, précoce et d’intensité modérée, s’est caractérisée par un impact particulièrement important chez les personnes âgées, lié à la circulation quasi-exclusive de virus A(H3N2) dans un contexte de couverture vaccinale insuffisante et d’efficacité vaccinale sub-optimale. Cette épidémie rappelle la gravité de la maladie et l’importance de la prévention, à savoir la vaccination chez les personnes à risque, qui doit être complétée de mesures barrières pour limiter la diffusion du virus dans l’entourage des cas.

Published
2017

39. 2015/16 I‐MOVE/I‐MOVE+ multicentre case‐control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage‐mismatched influenza B among children

Author

Kissling, Esther, Valenciano, Marta, Pozo, Francisco, Vilcu, Ana-Maria, Reuss, Annicka, Rizzo, Caterina, Larrauri, Amparo, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Korczyńska, Monika, Meijer, Adam, Machado, Ausenda, Ivanciuc, Alina, Višekruna Vučina, Vesna, Van Der Werf, Sylvie, Schweiger, Brunhilde, Bella, Antonino, Gherasim, Alin, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Paradowska-Stankiewicz, Iwona, Dijkstra, Frederika, Guiomar, Raquel, Lazar, Mihaela, Kurečić Filipović, Sanja, Johansen, Kari, Moren, Alain, and I-MOVE/I-MOVE+ Study Team

Subjects
case-control study, virus diseases, vaccine effe, influenza vaccine, influenza, 610 Medizin und Gesundheit, multicentre study, 3. Good health
Abstract

Background During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine. Methods We used the test‐negative design in a multicentre case‐control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza‐like illness (ILI) laboratory‐confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza‐positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group. Results We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5‐46.7). Among those aged 0‐14, 15‐64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: −32.3 to 65.0), 41.4% (95% CI: 20.5‐56.7) and 13.2% (95% CI: −38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: −4.1 to 56.7). Among those aged 0‐14, 15‐64 and ≥65 years, VE against influenza B was −47.6% (95% CI: −124.9 to 3.1), 27.3% (95% CI: −4.6 to 49.4) and 9.3% (95% CI: −44.1 to 42.9), respectively. Conclusions Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine.

40. Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016–17 and 2017–18)

Author

Kissling, Esther, Pozo, Francisco, Buda, Silke, Vilcu, Ana-Maria, Rizzo, Caterina, Gherasim, Alin, Horváth, Judit Krisztina, Brytting, Mia, Domegan, Lisa, Meijer, Adam, Paradowska-Stankiewicz, Iwona, Machado, Ausenda, Višekruna Vučina, Vesna, Lazar, Mihaela, Johansen, Kari, Dürrwald, Ralf, Van Der Werf, Sylvie, Bella, Antonino, Larrauri, Amparo, Ferenczi, Annamária, Zakikhany, Katherina, O'Donnell, Joan, Dijkstra, Frederika, Bogusz, Joanna, Guiomar, Raquel, Kurečić Filipović, Sanja, Pitigoi, Daniela, Penttinen, Pasi, Valenciano, Marta, and I-MOVE/I-MOVE+ Study Team

Subjects
Vaccine effectiveness, Europe, Influenza vaccine, Case-control study, 610 Medizin und Gesundheit, Influenza, multicentre study, 3. Good health
Abstract

Introduction Influenza A(H3N2) viruses predominated in Europe in 2016–17. In 2017–18 A(H3N2) and A(H1N1)pdm09 viruses co-circulated. The A(H3N2) vaccine component was the same in both seasons; while the A(H1N1)pdm09 component changed in 2017–18. In both seasons, vaccine seed A(H3N2) viruses developed adaptations/alterations during propagation in eggs, impacting antigenicity. Methods We used the test-negative design in a multicentre primary care case-control study in 12 European countries to measure 2016–17 and 2017–18 influenza vaccine effectiveness (VE) against laboratory-confirmed influenza A(H1N1)pdm09 and A(H3N2) overall and by age group. Results During the 2017–18 season, the overall VE against influenza A(H1N1)pdm09 was 59% (95% CI: 47–69). Among those aged 0–14, 15–64 and ≥65 years, VE against A(H1N1)pdm09 was 64% (95% CI: 37–79), 50% (95% CI: 28–66) and 66% (95% CI: 42–80), respectively. Overall VE against influenza A(H3N2) was 28% (95% CI: 17–38) in 2016–17 and 13% (95% CI: −15 to 34) in 2017–18. Among 0–14-year-olds VE against A(H3N2) was 28% (95%CI: −10 to 53) and 29% (95% CI: −87 to 73), among 15–64-year-olds 34% (95% CI: 18–46) and 33% (95% CI: −3 to 56) and among those aged ≥65 years 15% (95% CI: −10 to 34) and −9% (95% CI: −74 to 32) in 2016–17 and 2017–18, respectively. Conclusions Our study suggests the new A(H1N1)pdm09 vaccine component conferred good protection against circulating strains, while VE against A(H3N2) was

41. Estimation of seasonal influenza vaccine effectiveness using data collected in primary care in France: comparison of the test-negative design and the screening method

Author

Alessandra Falchi, Shirley Masse, M. Valette, Clément Turbelin, Vincent Enouf, Lisandru Capai, Sylvie Behillil, Thomas Hanslik, Thierry Blanchon, Louise Rossignol, Bruno Lina, Caroline Guerrisi, Cécile Souty, Ana-Maria Vilcu, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Génétique moléculaire des virus à ARN ((U-Pasteur_ 2 / UMR_3569)), Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), EA Bioscope Corse Méditerranée : Dynamique des infections virales en milieu insulaire, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pascal Paoli (UPP), Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie [UNIV Corse-Inserm] (EA7310), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Centre National de Référence Virus Influenza (Région Sud), Hospices Civils de Lyon (HCL), Laboratory of Virology East, Virpath-Grippe, de l'émergence au contrôle -- Virpath-Influenza, from emergence to control (Virpath), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Université Pascal Paoli (UPP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), VILCU, Ana-Maria, Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses, Université Paris Diderot - Paris 7 (UPD7)-Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus influenzae (Grippe)-Génétique moléculaire des virus à ARN (CNR), Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Corse-Inserm, Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Virologie [GH Nord HCL, Lyon] (CNR des virus influenza), Institut des Agents Infectieux [GH Nord HCL, Lyon]-Groupement Hospitalier Nord des HCL [Lyon], Service de Médecine Interne [AP-HP Hôpital Ambroise Paré], and AP-HP, Hôpital Ambroise Paré

Subjects
0301 basic medicine, Male, Primary health care, Seasonal influenza, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Screening method, Medicine, Mass Screening, 030212 general & internal medicine, Child, Aged, 80 and over, education.field_of_study, General Medicine, Middle Aged, 3. Good health, virology, Infectious Diseases, Treatment Outcome, Influenza Vaccines, Child, Preschool, Epidemiological Monitoring, surveillance, Female, France, Microbiology (medical), Adult, Adolescent, 030106 microbiology, Population, Primary care, 03 medical and health sciences, Young Adult, primary care, [SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology, Influenza, Human, Humans, education, Aged, Estimation, Primary Health Care, vaccine effectiveness, business.industry, Infant, Newborn, Infant, Confidence interval, Influenza, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Immunology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Demography
Abstract

International audience; Objectives: We discussed which method between the test-negative design (TND) and the screening method (SM) could provide more robust real-time and end-of-season vaccine effectiveness (VE) estimates using data collected from routine influenza surveillance in primary care. Methods: We used data collected during two influenza seasons, 2014e15 and 2015e16. Using the SM, we estimated end-of-season VE in preventing medically attended influenza-like illness and laboratory-confirmed influenza among the population at risk. Using the TND, we estimated end-of-season VE in preventing influenza among both the general and the at-risk population. We estimated real-time VE using both methods. Results: For the SM, the overall adjusted end-of-season VE was 24% (95% confidence interval (CI), 16 to 32) and 12% (95% CI, À16 to 33) during season 2014e15, and 53% (95% CI, 44 to 60) and 47% (95% CI, 23 to 64) during season 2015e16, in preventing influenza-like illness and laboratory-confirmed influenza, respectively. For the TND, the overall adjusted end-of-season VE was À17% (95% CI, À79 to 24) and À38% (95% CI, À199 to 13) in 2014e15, and 10% (95% CI, À31 to 39) and 18% (95% CI, À33 to 50) in 2015e16, among the general and at-risk population, respectively. Real-time VE estimates obtained through the TND showed more variability across each season and lower precision than those estimated with the SM. Conclusions: Although the worldwide use of the TND allows for comparison of overall VE estimates among countries, the SM performs better in providing robust real-time VE estimates among the population at risk. A.M. Vilcu, Clin Microbiol Infect 2018;24:431.e5e431.e12

Published
2018
Full Text
View/download PDF

42. Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned.

Author

Bagaria J, Jansen T, Marques DF, Hooiveld M, McMenamin J, de Lusignan S, Vilcu AM, Meijer A, Rodrigues AP, Brytting M, Mazagatos C, Cogdale J, van der Werf S, Dijkstra F, Guiomar R, Enkirch T, and Valenciano M

Subjects
Europe epidemiology, Humans, Pandemics prevention & control, Primary Health Care, Sentinel Surveillance, COVID-19 epidemiology, Influenza Vaccines, Influenza, Human epidemiology, Influenza, Human prevention & control
Abstract

As the COVID-19 pandemic began in early 2020, primary care influenza sentinel surveillance networks within the Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE) consortium rapidly adapted to COVID-19 surveillance. This study maps system adaptations and lessons learned about aligning influenza and COVID-19 surveillance following ECDC / WHO/Europe recommendations and preparing for other diseases possibly emerging in the future. Using a qualitative approach, we describe the adaptations of seven sentinel sites in five European Union countries and the United Kingdom during the first pandemic phase (March-September 2020). Adaptations to sentinel systems were substantial (2/7 sites), moderate (2/7) or minor (3/7 sites). Most adaptations encompassed patient referral and sample collection pathways, laboratory testing and data collection. Strengths included established networks of primary care providers, highly qualified testing laboratories and stakeholder commitments. One challenge was the decreasing number of samples due to altered patient pathways. Lessons learned included flexibility establishing new routines and new laboratory testing. To enable simultaneous sentinel surveillance of influenza and COVID-19, experiences of the sentinel sites and testing infrastructure should be considered. The contradicting aims of rapid case finding and contact tracing, which are needed for control during a pandemic and regular surveillance, should be carefully balanced.

Published
2022
Full Text
View/download PDF

43. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021.

Author

Kissling E, Hooiveld M, Martínez-Baz I, Mazagatos C, William N, Vilcu AM, Kooijman MN, Ilić M, Domegan L, Machado A, de Lusignan S, Lazar M, Meijer A, Brytting M, Casado I, Larrauri A, Murray JK, Behillil S, de Gier B, Mlinarić I, O'Donnell J, Rodrigues AP, Tsang R, Timnea O, de Lange M, Riess M, Castilla J, Pozo F, Hamilton M, Falchi A, Knol MJ, Kurečić Filipović S, Dunford L, Guiomar R, Cogdale J, Cherciu C, Jansen T, Enkirch T, Basile L, Connell J, Gomez V, Sandonis Martín V, Bacci S, Rose AM, Pastore Celentano L, and Valenciano M

Subjects
COVID-19 Vaccines, Europe epidemiology, Humans, Primary Health Care, SARS-CoV-2, Vaccination, COVID-19 epidemiology, COVID-19 prevention & control, Influenza Vaccines, Influenza, Human prevention & control
Abstract

IntroductionIn July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe.AimUsing a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection.MethodsIndividuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination.ResultsOverall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms.ConclusionsVE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.

Published
2022
Full Text
View/download PDF

44. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.

Author

Kissling E, Hooiveld M, Sandonis Martín V, Martínez-Baz I, William N, Vilcu AM, Mazagatos C, Domegan L, de Lusignan S, Meijer A, Machado A, Brytting M, Casado I, Murray JK, Belhillil S, Larrauri A, O'Donnell J, Tsang R, de Lange M, Rodrigues AP, Riess M, Castilla J, Hamilton M, Falchi A, Pozo F, Dunford L, Cogdale J, Jansen T, Guiomar R, Enkirch T, Burgui C, Sigerson D, Blanchon T, Martínez Ochoa EM, Connell J, Ellis J, van Gageldonk-Lafeber R, Kislaya I, Rose AM, and Valenciano M

Subjects
Adult, Aged, COVID-19 Vaccines, Europe, Humans, Primary Health Care, COVID-19, SARS-CoV-2
Abstract

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

Published
2021
Full Text
View/download PDF

45. Influenza epidemics observed in primary care from 1984 to 2017 in France: A decrease in epidemic size over time.

Author

Souty C, Amoros P, Falchi A, Capai L, Bonmarin I, van der Werf S, Masse S, Turbelin C, Rossignol L, Vilcu AM, Lévy-Bruhl D, Lina B, Minodier L, Dorléans Y, Guerrisi C, Hanslik T, and Blanchon T

Subjects
Adolescent, Adult, Aged, Child, Child, Preschool, Female, France epidemiology, Humans, Incidence, Infant, Infant, Newborn, Male, Middle Aged, Time Factors, Vaccination statistics & numerical data, Vaccination Coverage, Young Adult, Epidemics statistics & numerical data, Influenza, Human epidemiology, Primary Health Care statistics & numerical data, Sentinel Surveillance
Abstract

Background: Epidemiological analysis of past influenza epidemics remains essential to understand the evolution of the disease and optimize control and prevention strategies. Here, we aimed to use data collected by a primary care surveillance system over the last three decades to study trends in influenza epidemics and describe epidemic profiles according to circulating influenza viruses., Methods: Influenza-like illness (ILI) weekly incidences were estimated using cases reported by general practitioners participating in the French Sentinelles network, between 1984 and 2017. Influenza epidemics were detected by applying a periodic regression to this time series. Epidemic (co-)dominant influenza virus (sub)types were determined using French virology data., Results: During the study period, 297 607 ILI cases were reported allowing the detection of 33 influenza epidemics. On average, seasonal epidemics lasted 9 weeks and affected 4.1% of the population (95% CI 3.5; 4.7). Mean age of cases was 29 years. Epidemic size decreased over time by -66 cases per 100 000 population per season on average (95% CI -132; -0.2, P value = 0.049) and epidemic height decreased by -15 cases per 100 000 (95% CI -28; -2, P value = 0.022). Epidemic duration appeared stable over time. Epidemics were mostly dominated by A(H3N2) (n = 17, 52%), associated with larger epidemic size, higher epidemic peak and older age of cases., Conclusions: The declining trend in influenza epidemic size and height over the last 33 years might be related to several factors like increased vaccine coverage, hygiene improvements or changing in influenza viruses. However, further researches are needed to assess the impact of potential contributing factors to adapt influenza plans., (© 2018 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.)

Published
2019
Full Text
View/download PDF

46. Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I-MOVE multicentre test-negative case-control study, 2011/2012-2016/2017.

Author

Valenciano M, Kissling E, Larrauri A, Nunes B, Pitigoi D, O'Donnell J, Reuss A, Horváth JK, Paradowska-Stankiewicz I, Rizzo C, Falchi A, Daviaud I, Brytting M, Meijer A, Kaic B, Gherasim A, Machado A, Ivanciuc A, Domegan L, Schweiger B, Ferenczi A, Korczyńska M, Bella A, Vilcu AM, Mosnier A, Zakikhany K, de Lange M, Kurečić Filipovićović S, Johansen K, and Moren A

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult, Influenza Vaccines administration & dosage, Influenza Vaccines immunology, Influenza, Human prevention & control
Abstract

Background: Results of previous influenza vaccination effects on current season influenza vaccine effectiveness (VE) are inconsistent., Objectives: To explore previous influenza vaccination effects on current season VE among population targeted for vaccination., Methods: We used 2011/2012 to 2016/2017 I-MOVE primary care multicentre test-negative data. For each season, we compared current season adjusted VE (aVE) between individuals vaccinated and unvaccinated in previous season. Using unvaccinated in both seasons as a reference, we then compared aVE between vaccinated in both seasons, current only, and previous only., Results: We included 941, 2645 and 959 influenza-like illness patients positive for influenza A(H1N1)pdm09, A(H3N2) and B, respectively, and 5532 controls. In 2011/2012, 2014/2015 and 2016/2017, A(H3N2) aVE point estimates among those vaccinated in previous season were -68%, -21% and -19%, respectively; among unvaccinated in previous season, these were 33%, 48% and 46%, respectively (aVE not computable for influenza A(H1N1)pdm09 and B). Compared to current season vaccination only, VE for both seasons' vaccination was (i) similar in two of four seasons for A(H3N2) (absolute difference [ad] 6% and 8%); (ii) lower in three of four seasons for influenza A(H1N1)pdm09 (ad 18%, 26% and 29%), in two seasons for influenza A(H3N2) (ad 27% and 39%) and in two of three seasons for influenza B (ad 26% and 37%); (iii) higher in one season for influenza A(H1N1)pdm09 (ad 20%) and influenza B (ad 24%)., Conclusions: We did not identify any pattern of previous influenza vaccination effect. Prospective cohort studies documenting influenza infections, vaccinations and vaccine types are needed to understand previous influenza vaccinations' effects., (© 2018 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results